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Abstract
Background: Although a high level of functional voltage-gated sodium channel (VGSC) expression
has been found in strongly metastatic human and rat prostate cancer (PCa) cells, the mechanism(s)
responsible for the upregulation is unknown. The concentration of epidermal growth factor (EGF),
a modulator of ion channels, in the body is highest in prostatic fluid. Thus, EGF could be involved
in the VGSC upregulation in PCa. The effects of EGF on VGSC expression in the highly metastatic
human PCa PC-3M cell line, which was shown previously to express both functional VGSCs and
EGF receptors, were investigated. A quantitative approach, from gene level to cell behaviour, was
used. mRNA levels were determined by real-time PCR. Protein expression was studied by
Western blots and immunocytochemistry and digital image analysis. Functional assays involved
measurements of transverse migration, endocytic membrane activity and Matrigel invasion.
Results: Exogenous EGF enhanced the cells' in vitro metastatic behaviours (migration, endocytosis
and invasion). Endogenous EGF had a similar involvement. EGF increased VGSC Nav1.7
(predominant isoform in PCa) mRNA and protein expressions. Co-application of the highly specific
VGSC blocker tetrodotoxin (TTX) suppressed the effect of EGF on all three metastatic cell
behaviours studied.
Conclusion: 1) EGF has a major involvement in the upregulation of functional VGSC expression
in human PCa PC-3M cells. (2) VGSC activity has a significant intermediary role in potentiating
effect of EGF in human PCa.
Background
Although prostate cancer (PCa) is the most commonly
occurring cancer in males over the age of 65 [1], many
problems remain in its clinical management, as regards
both definitive diagnosis and long-lasting therapy [2]. A
novel 'neuroscience' approach to understanding the
pathophysiology of PCa suggested that upregulation of
voltage-gated Na+ channels (VGSCs) could be an acceler-
ating factor in metastatic disease [3]. Thus, we have shown
previously that functional VGSC expression could distin-
guish strongly and weakly metastatic human and rat PCa
cells [4,5]. Importantly, application of tetrodotoxin
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VGSC activity could directly enhance metastatic ability by
potentiating a range of in vitro cellular behaviours integral
to the metastatic cascade: morphological enhancement
[6], directional motility [7], secretory membrane activity
[8], adhesion [9], gene expression, including auto-regula-
tion [10] and invasion [4,5,11]. In fact, over-expression of
VGSC alone was found to be "necessary and sufficient" to
confer invasive potential on non-metastatic human PCa
cells [12].
The catalytic/pore-forming VGSC α- subunit (VGSCα)
responsible for the functional activity was found to be
Nav1.7, upregulated at mRNA level by > 1000-fold in
strongly vs weakly metastatic rat and human PCa cells
[13]. Furthermore, VGSCα protein and Nav1.7 mRNA
expression were also markedly up-regulated in human
PCa in vivo [14]. In fact, analysis of "receiver- operator
characteristics" suggested that Nav1.7 could serve as an
effective functional diagnostic marker for PCa [14].
However, the mechanism(s) responsible for the func-
tional VGSC expression in metastatic PCa is not known.
VGSCs have been found to be regulated by growth factors,
such as fibroblast growth factor (FGF), nerve growth fac-
tor (NGF), epidermal growth factor (EGF), in various
human and rat cell lines, such as pheochromocytoma
PC12 cells [15-17] and rat PCa Mat-LyLu cells [18,19]. On
another front, it has also been emphasised that growth
factors could play a major role in progression of human
PCa [e.g. [20,21]]. Moreover, increased EGF expression
also has been confirmed in human PCa in vivo [22]. Thus,
there is the following possible triangular relationship (Fig.
1) and EGF could be responsible for the VGSC upregula-
tion in PCa. This possibility has been tested in the present
study using the strongly metastatic human prostate epi-
thelial PC-3M cell model which expresses both functional
VGSCs [5] and EGF receptors [23].
Results
The overall approach was as follows: 1) Effects of exoge-
nous EGF on PC-3M metastatic cell behaviours (MCBs)
were tested; (2) possible involvement of VGSC activity in
the EGF-induced effects was determined; and (3) the level
(mRNA or protein) at which such VGSC involvement
could occur was elucidated. The results obtained are
described below hierarchically, from functional to molec-
ular aspects.
Effects of EGF on in vitro metastatic cell behaviours
Exogenous EGF (1–100 ng/ml) significantly increased
transverse migration of PC-3M cells in a dose dependent
manner (p < 0.05 for all concentrations; n = 9; Fig. 2A and
2B). The greatest effect was seen for 50 ng/ml EGF, which
increased migration by 39 ± 1.2 % (Fig. 2A &2B). In most
of the experiments that followed, working concentrations
of EGF around this peak (i.e., 20, 50 or 100 ng/ml) were
used. In endocytosis assays, treatment with EGF (20 ng/
ml) enhanced HRP uptake by 23 ± 5.4 % (p = 0.01; n = 9;
Fig. 2C). This effect was also concentration dependent
(Fig. 2D). Interestingly, in both assays, increasing the EGF
concentration ultimately produced reduced effects (Fig.
2B &2D). In Boyden chamber invasion assays, EGF (100
ng/ml) increased the cells' invasiveness by 20 ± 5.2 % (p
< 0.03 cf. control; n = 4; Fig. 2E). Application of 100 nM
AG1478, an inhibitor of EGF receptor, alone had the
opposite effect, reducing cell invasion by 19 ± 5.4 % (p =
0.02, n = 4; Fig. 2E). This result suggested that the poten-
tiating effect of EGF on MCBs also occurred endog-
enously.
All three assays were consistent, therefore, in showing that
EGF enhanced PC-3M cells' in vitro MCBs.
VGSC involvement in the effects of exogenous EGF
In all 3 functional assays used, application of TTX (500
nM) alone reduced MCBs: Migration (by 11 ± 2.3 %; p <
0.01; n = 6), endocytosis (by 18 ± 3.5 %; p = 0.02; n = 9)
and invasion (by 19 ± 5.2 %; p = 0.04; n = 4).) (Fig. 2A, C
&2E). The effects of TTX were dose-dependent (not
shown). Importantly, TTX when co-applied substantially
blocked the enhancement effects of exogenous EGF (20 –
100 ng/ml) in all 3 assays (Fig. 2A, C &2E). In the case of
migration and endocytosis, there was a strong blocking
effect of TTX on the EGF-induced enhancement; thus, for
TTX vs EGF + TTX, P = 0.23 (migration) and P = 0.12
(endocytosis), ie EGF had no effect in the presence of TTX.
Essentially the same effect was observed for invasion (Fig.
2E), although the difference in the values of InvI for TTX
and EGF + TTX was only just not significant (P = 0.051).
Thus, again, TTX blocked the effect of EGF in enhancing
invasion.
The possible triangular relationship between EGF, VGSC and PCaFigure 1
The possible triangular relationship between EGF, VGSC and 
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Functional evidence for EGF-induced enhancement of metastatic cell behaviours via VGSC expression/activity in PC-3M cellsigure 2
Functional evidence for EGF-induced enhancement of metastatic cell behaviours via VGSC expression/activity in PC-3M cells. 
(A) Migration index (MiI), expressed relative to the control level (Cont), fixed as 100 %. Effects of EGF (50 ng/ml), TTX (500 
nM) and EGF+TTX are shown. (B) Dose dependence of the effect of EGF on MiI. ∆MiI denotes the percentage change 
(increase) in MiI induced by increasing concentrations of EGF, expressed relative to the maximum (fixed as 100 %) seen for 50 
ng/ml. (C) Endocytosis index (EI), expressed as percentage of the control level (Cont). Effects of EGF (20 ng/ml), TTX (500 nM) 
and EGF+TTX are shown. (D) Dose dependence of the effect of EGF on EI. ∆EI denotes the change (increase) in EI induced by 
given concentrations of EGF. (E) Boyden chamber invasion assay data. Effects of EGF (100 ng/ml), TTX (500 nM), EGF+TTX 
and AG1478 (100 nM) are shown. Invasion index (InvI) denotes the percentage of cells crossing the membrane in Transwell 
assays. Each data point or histobar denotes mean ± standard error (n = 4).
Molecular Cancer 2007, 6:76 http://www.molecular-cancer.com/content/6/1/76It was concluded that for all 3 in vitro functional assays,
EGF potentiated MCBs primarily via VGSC activity.
Effects of EGF on VGSC mRNA and protein levels
Application of EGF (50 and 100 ng/ml) to PC-3M cells for
24 h caused significant (2- and 5.5- fold, respectively)
increases in mRNA expression of Nav1.7, the predomi-
nant VGSC subtype expressed in these cells (p < 0.01; n =
4 for both concentrations; Fig. 3A). Treatment with
AG1478 (100 nM) reduced the basal Nav1.7 mRNA level
by 70 ± 2.1 % (p < 0.01; n = 4; Fig. 3A). Co-treatment with
AG1478 abolished the effect of exogenous EGF on Nav1.7
mRNA levels (Fig. 3A).
Similar treatment with EGF (50 and 100 ng/ml) caused
increases in total VGSC protein expression by 16 ± 1.5 and
28 ± 2.1 %, respectively (for both: p < 0.01, n = 6; Fig. 3B
&3C). In contrast, AG1478 suppressed total VGSC protein
expression by 22 ± 3.1 % (p < 0.01; n = 6; Fig. 3B &3C).
AG1478 also suppressed the effect of exogenous EGF in
upregulating total VGSC protein expression; there was no
difference in the levels of VGSC protein expression for
EGF+AG1478 and AG1478 (p > 0.05; n = 6; Fig. 3B &3C).
The effect of EGF (exogenous and endogenous) in increas-
ing VGSC protein expression was also apparent in plasma
membrane (PM). Thus, exogenous EGF (100 ng/ml) and
AG1478 (100 nM) altered PM expression by +20 ± 2.0
and -15 ± 2.6 %, respectively (for both: p < 0.01; n = 5;
Figs. 4Ai–iii &3B). In a preliminary experiment (n = 2), an
alternative method, involving cell surface biotinylation
similarly showed that EGF increased plasma membrane
VGSC protein expression (Fig. 4C, lane 4 vs 3).
Finally, the possible effect of EGF on sub-cellular distribu-
tion of VGSC protein expression was investigated by
immunocytochemistry, confocal microscopy and digital
imaging (Fig. 5). This analysis showed that plasma mem-
brane VGSC protein expression increased by 260 ± 3.2 %
(p = 0.01; n = 18; Fig. 5C). In contrast, there was no signif-
icant change in the VGSC immunoreactivity of the intrac-
ellular compartment (Fig. 5C).
It was concluded that EGF increased Nav1.7 mRNA
expression, leading to de novo VGSC protein synthesis,
directed mainly to plasma membrane.
Auto-regulation of VGSC protein expression
Taking together the data obtained here (using the strongly
metastatic human PCa PC-3M cell line) and the data
obtained previously from analogous rat PCa Mat-LyLu
cells [10] (both with Nav1.7 dominant), VGSC expression
would appear to be under auto-regulation. Accordingly,
long-term (24+ h) treatment with TTX led to down-regu-
lation of functional VGSC expression. Thus, application
of TTX (500 nM) alone reduced total and plasma mem-
brane VGSC protein expressions by 12 ± 1.5 % and 10 ±
1.4 %, respectively (p < 0.01 for both; n = 5–6; Fig. 6).
Interestingly, even when EGF (50 and 100 ng/ml) was
added in the presence of TTX, protein expressions
remained below control levels. Thus, the auto-regulation
by positive feed-back appeared to dominate the normally
potentiating effect of EGF.
Discussion
The main results of the present study are as follows: 1)
EGF increased VGSC mRNA and protein expression; the
latter was largely targeted to the plasma membrane. (2)
Exogenous EGF enhanced PC-3M cells' in vitro metastatic
behaviours (migration, endocytosis and invasion).
Endogenous EGF appeared to have a similar involvement.
(3) The potentiating effects of EGF on MCBs were medi-
ated substantially by VGSC activity. (4) VGSC expression
also was under auto-regulation by activity-dependent pos-
itive feed-back which dominated the effect of EGF.
Role of EGF in PCa
Prostate cancer is extremely heterogeneous in stage and
grade of tumours within individual glands and this adds
to the complexity of its diagnosis [24]. As regards therapy,
whilst androgen ablation works for a few years, hormone
resistance ultimately sets in and this may coincide with
PCa progression becoming dependent on growth factor
signalling [25]. A key such growth factor may be EGF
which has a well known role in embryogenesis, cellular
differentiation, proliferation and angiogenesis. A high
level of EGF immunoreactivity has been shown in normal
rat prostate [26] and this may be controlled by androgen
[27]. Androgen receptor can interact with EGFR signalling
and this can regulate invasiveness [28]. In fact, the highest
concentration of EGF in body (~175 ng/ml) occurs in
prostate [29], comparable to the concentrations used in
the present study. Upregulation of EGF/EGFR expression
has been reported in metastatic PCa [30]. Exogenous EGF
has been shown to enhance migration and invasion of
various cell lines, including rat PCa Mat-LyLu cells [19].
The present study showed that EGF (exogenous and
endogenous) enhanced the in vitro MCBs of the strongly
metastatic PC-3M cells. Taken together, this evidence sup-
ports the notion that EGF signalling is closely associated
with progression of PCa to the metastatic mode. Accord-
ingly, EGF receptor antagonists or tyrosine kinase blockers
are potential anti-PCa drugs [31].
Regulation of functional VGSC expression by EGF
Our essential result and hypothesis to follow are that EGF
induced upregulation of Nav1.7 mRNA and VGSC protein
synthesis, most of which was inserted in plasma mem-
brane and led to the observed enhancement of MCBs. We
have shown previously for (rat and human) PCa cells thatPage 4 of 12
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Effects of EGF on VGSC mRNA and protein expression in PC-3M cellsFigure 3
Effects of EGF on VGSC mRNA and protein expression in PC-3M cells. (A) Real-time PCR measurements of Nav1.7 mRNA 
expression. Data are plotted as fold-differences relative to the control (Cont) level (dotted line). All treatments were for 24 
hours. Treatments were as follows: EGF1 (50 ng/ml), EGF2 (100 ng/ml), AG1478 (100 nM), and EGF1/2+AG1478. EGF signifi-
cantly enhanced mRNA expression, and this was suppressed by co-treatment with AG1478 (100 nM). (B) A typical Western 
blot of effects on total VGSC protein expression (50 µg of protein per lane) over 24 h, with pan-VGSCα and anti-actinin anti-
bodies. Arrows indicate molecular weights of ~220 kDa (for VGSCα) and ~100 kDa (for actinin). The lanes denote the follow-
ing: 1) Control (Cont.; cells in 0.5 % FBS); (2) EGF1 (50 ng/ml); (3) EGF2 (100 ng/ml); (4) AG1478 (100 nM); and (5) EGF1 + 
AG1478. (C) Quantification and averaging of the data shown in (B) with the corresponding conditions (1–5). VGSC protein 
expression wasquantified from band optical density. Each histobar (in A and C)denotes mean ± standard error (n = 4–6).
Molecular Cancer 2007, 6:76 http://www.molecular-cancer.com/content/6/1/76VGSC activity potentiates a range of cellular behaviours
integral to the metastatic cascade, including morphologi-
cal development [6], adhesion [9], transverse migration,
endocytic membrane activity and invasion (present study;
also, [10]). EGF-induced upregulation of VGSC activity
has been shown previously in PC12 cells [17], and, more
recently, in Mat-Lylu strongly metastatic rat PCa cells [19].
At present, the signalling cascades responsible for the
observed transcriptional upregulation of VGSC in PC-3M
cells is not known. There are 4 main transduction mecha-
nism(s) associated with EGFR signalling: Stat, PLCγ, PI3K
and MAPK [32]. It is possible that VGSC expression/activ-
ity was controlled at a variety of levels from transcription
to post-translation, including mRNA stability and phos-
phorylation by PKC or PKA [e.g. [33]]. Further work is
required to elucidate these aspects.
Confocal microscopy and densitometric analysis of VGSC protein expression in PC-3M cellsFigure 4
Confocal microscopy and densitometric analysis of VGSC protein expression in PC-3M cells. (A). Typical confocal images. (i) 
Control. (ii) EGF (100 ng/ml). (iii) AG1478 (100 nM). Each treatment was for 24 h. Scale bar, 20 µm (applicable to all panels). 
(B) Signal density, ie optical density of plasma membrane (PM) VGSC immunocytochemistry, corresponding to images such as 
(A). Each histobar denotes mean ± standard error (n = 50 cells/3 separate experiments). (C) Effects of EGF (similar treatment 
as in A) on total and PM VGSC expression. The PM fraction was immunoprecipitated by biotin labelling. Key: 1) Control total 
VGSC protein. (2) EGF-treated total VGSC protein. (3) Control PM VGSC protein. (4) EGF-treated PM VGSC protein. Note 
the change in the molecular size of the biotinylated fractions (lanes 3 & 4).Page 6 of 12
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Effect of EGF on sub-cellular distribution of VGSC protein expression, determined by immunocytochemistry, confocal micros-copy and digital imagingFigure 5
Effect of EGF on sub-cellular distribution of VGSC protein expression, determined by immunocytochemistry, confocal micros-
copy and digital imaging. VGSC expression was denoted by the fluorescence intensity (arbitrary units; AU) of the immunocyto-
chemical label. (A) Typical profile of VGSC protein expression scanned across the cell. (B) Same as (A) after treatment with 
EGF (100 ng/ml) for 24 h. (C) Data quantified from profiles shown in (A) and (B) dividing the cellular cross-sections into cyto-
plasmic/internal ("INT") and plasma membrane ("PM") fractions, as described in the Methods. Each histobar denotes mean ± 
standard error (n = 18 cells from 3 separate experiments for each condition).
Molecular Cancer 2007, 6:76 http://www.molecular-cancer.com/content/6/1/76Although blocking VGSC activity with TTX suppressed
EGF-induced enhancement of endocytosis and migration,
the statistical analysis suggested that the involvement of
VGSC in invasion was somewhat less. It is highly likely, in
fact, that EGF would have parallel affects upon other func-
tional cellular components involved in metastatic behav-
iour, including actin cytoskeleton [34], focal adhesion
kinase [35] and Ca2+ signalling [36]. A similar conclusion
was reached from a similar study on rat PCa cells [19].
VGSC expression in PC-3M cells was also under auto-reg-
ulation by activity-dependent positive feed-back, such
that blocking channel activity with TTX for 24 h would
down-regulate its expression in plasma membrane. Such
a mechanism was shown to occur in analogous strong
metastatic rat PCa Mat-LyLu cells and involved PKA acti-
vated by the Na+ influx occurring via active VGSCs [10].
The present study showed that a comparable feed-back
mechanism also operates in human PCa cells, although it
is not known if this also involves PKA as an intermediary.
This auto-regulatory mechanism is robust and, if blocked,
the up-regulatory effect of EGF was lost. It would follow,
therefore, that EGF and VGSC are inter-connected in the
regulation of functional VGSC expression and control of
MCBs.
Possible role of other growth factors and VGSC association 
in PCa
A number of other growth factors have also been associ-
ated with metastatic PCa. These include NGF [37], FGF
[38], transforming growth factor-beta [39], vascular
endothelial growth factor [40] and hepatocyte growth fac-
tor [41]. Some of these growth factors have also been
shown to regulate VGSC activity e.g. [42]. The case of NGF
is interesting since its concentration outside the nervous
system is highest in the prostate. NGF was shown previ-
ously also to induce upregulation of VGSC expression/
activity in PC12 cells [43], frog sympathetic B neurons
[44], human astrocytoma cell lines (1321N1 and A172)
[45] and rat PCa Mat-LyLu cells [10]. Importantly, how-
ever, although NGF also potentiated MCBs in Mat-LyLu
cells, this did not occur via VGSC activity. It would seem,
therefore, that the multitude of growth factors that occur
in prostate may contribute to metastatic disease in differ-
ent ways; this is likely to be a dynamic process and may be
compartmentalised.
EGF – VGSC interactions in PCa
Taking the available evidence, including the results of the
present study together, a scheme of dual regulation VGSC
expression/activity by EGF and feed-back can be consid-
ered for metastatic PCa, modelled here by PC-3M cells. In
the main part, EGF is tonically released from PCa cells,
consistent with the effect of AG1478 alone, also, [46,47].
This would upregulate VGSC expression/activity, thus
potentiating MCBs. VGSC activity enhances secretory
membrane activity in PCa cells, as indicated by the results
of the endocytosis assays (also [8]). If VGSC activity con-
trolled the release of EGF (eg via vesicular trafficking), it
could lead to the following positive feed-back: VGSC
activity → EGF release → VGSC upregulation etc. [48]. In
a further loop, VGSC activity auto-regulates itself also by
positive feed-back, as detailed previously for analogous
rat PCa cells [10]. It is possible, in fact, that the two loops
'overlap' to some extent, and PKA may be a common fac-
tor [49]. Importantly, under conditions when VGSC activ-
ity was blocked, upregulation of VGSC protein expression
(total or in plasma membrane) by EGF was not seen. It
would follow, therefore that VGSC expression/activity is a
key gate in progression of EGF-dependent (androgen-
independent?) PCa. Accordingly, the metastatic process in
PCa would be accelerated significantly by the two positive
feed-back mechanisms (up)regulating VGSC expression.
Further fine-tuning of this control mechanism may occur
via interactions within the EGF system itself whereby, for
example, EGF can control EGFR expression and vice versa,
in autocrine fashion [50].
Effects of TTX (500 nM) and TTX+EGF on respective rela-tiv  levels of total and plasma membrane (PM) VGSC p otein expr sion, presented as a perc ntages of respective con-rols (C t)Figure 6
Effects of TTX (500 nM) and TTX+EGF on respective rela-
tive levels of total and plasma membrane (PM) VGSC protein 
expression, presented as a percentages of respective con-
trols (Cont). Two concentrations of EGF were used: 50 ng/
ml (EGF1) and 100 ng/ml (EGF2). Relative levels of total 
VGSC were deduced from Western blots (as in Fig. 2). Rela-
tive levels of PM expression were obtained from immunocy-
tochemistry/digital analysis(as in Fig. 4). Each histobar 
denotes mean ± standard error (n = 3–6). Light bars, total 
VGSC protein. Shaded bars, VGSC protein expressed in 
plasma membrane (PM).Page 8 of 12
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VGSC (Nav1.7) in clinical management of PCa [51]. We
have shown previously that Nav1.7 expression has suffi-
cient sensitivity and selectivity to be an effective diagnos-
tic marker for metastatic PCa [14]. In fact, the biology of
the VGSC (in being upregulated by growth factors, such as
EGF, and enhancing various MCBs) is consistent with it
being an early event in progression of PCa to metastasis.
Suppression of VGSC activity directly using channel
blockers, therefore, could have therapeutic potential.
Indeed, VGSC-blocking anti-convulsant drugs have been
shown to be cytostatic inhibitors of PCa [52]. The present
work also raises the possibility of developing additionally
effective combination therapy, aimed at concurrent block-
age of VGSC activity and EGF signalling.
Conclusion
The main conclusion is that EGF has a major involvement
in the upregulation of functional VGSC expression in PC-
3M human PCa cells. In turn, VGSC activity enhances the
cells' in vitro migration, endocytosis and invasion. The
effect of EGF is transcriptional, at least in part, and the de
novo protein produced is largely targeted to the plasma
membrane. VGSC expression is also under auto-regula-
tion by activity-dependent positive feed-back. Thus, VGSC
expression/activity could be a major intermediary of the
potentiating effect of EGF in human PCa.
Methods
Cell culture and pharmacological treatments
PC-3M cells were maintained in RPMI medium (without
phenol red) supplemented with 10 % foetal bovine serum
(FBS) and 1 % L-glutamine, in a humidified 37°C incuba-
tor with 5 % CO2 . Prior to any pharmacological treat-
ment, cells were first 'conditioned' in 0.5 % FBS for 24 h.
0.5 % FBS was determined as a optimum by testing the
effect of a range of FBS concentrations on cell viability
(data not shown). Cells were then incubated in one of the
following: (1) EGF; (2) TTX; (3) EGF+TTX; (4) AG1478;
an inhibitor of EGF receptor tyrosine kinase [53] or (5)
EGF+AG1478. All pharmacological agents were applied in
0.5 % FBS for 24 h.
In vitro metastatic cell behaviour assays
Initial 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assays showed that there was no pro-
liferative effect of any of the pharmacological agents at
their working concentrations. Lack of effect of EGF on
proliferation of PCa cells has also been reported before
[54-56]. Also, none of the treatments had any effect on
cell viability, monitored using trypan blue staining. Three
different assays of in vitro metastatic cell behaviour (MCB)
were carried out, as follows:
1. Transwell migration. Details of this assay were described
previously [57]. Essentially, conditioned cells seeded in
multi-well dishes were pharmacologically treated and
then re-suspended using trypsin-EDTA and plated at a
density of 20 × 104 cells/well onto 12 µm pore Transwell
filters with polycarbon membrane (Corning, MA, USA).
Following 6 h incubation, MTT was used to determine the
number of migrated cells. These measurements were plot-
ted as the percentage (%) of the readings for migrated
cells/original cell number, giving "Migration Index
(MiI)".
2. Endocytic membrane activity. This followed the procedure
originally described by Onganer and Djamgoz [58].
Briefly, cells were seeded in multi-well dishes at a density
of 5 × 104 cells/well in normal medium. Endocytosis was
measured by optimised (0.5 mg/ml for 40 min) uptake of
horseradish peroxidase (HRP type IV; Sigma). Endogene-
ous peroxidase activity was measured in parallel in every
experiment and subtracted from the uptake. The differ-
ence in the optical densities was assumed to represent true
endocytosis and plotted as the percentage of the control
level in untreated cells, giving "Endocytosis Index, EI
(%)".
3. Matrigel invasion. Boyden invasion chambers with 8 µm
pore size inserts pre-coated with Matrigel basement mem-
brane matrix were used in accordance with the manufac-
turer's instructions (BD BioSciences, MA, USA) [4,57].
Cells were plated at a density 7.5 × 104 /well and each
treatment was repeated three times. The optical density of
the invaded cell population was measured after 24 h and
plotted as a percentage of the original cell number, giving
"Invasion Index, InvI (%)".
Real-time PCR
Total RNA was isolated using a RNA miniprep kit accord-
ing to the manufacturer's instructions (Stratagene, CA,
USA). RNA quality was assessed by gel electrophoresis
and its quantity was determined by spectrophotometric
analysis. cDNA was generated by reverse transcriptase
reaction and used for real time PCR (rt-PCR). The primer
sequences for Nav1.7 were as follows:
5'-TATGACCATGAATAACCCGC-3'; and
5-'TCAGGTTTCCCATGAACAGC-3'
The annealing temperature is 60°C; [13]. Quantification
of mRNA levels was performed by SYBR Green technol-
ogy, using a DNA Engine Opticon 2 System (MJ
Research). The mRNA levels were calculated by the 2-∆∆CT
method [59], with beta actin as the normalising gene [60].
Additional PCRs confirmed expression of EGF receptors
in PC-3M cells (not shown) [23].Page 9 of 12
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Proteins were extracted as described before [5] and pre-
pared according to the instructions of the manufacturer
(Upstate Biotechnology, Buckingham, UK). Protein yield
was determined by spectrophotometry. The primary anti-
body was a pan-VGSC (Upstate Biotechnology, Bucking-
ham, UK). The secondary antibody was a peroxidase-
conjugated swine anti-rabbit immunoglobulin (DAKO,
Glostrup, Denmark). The nitrocellulose membrane was
stripped and treated with an anti-actinin antibody (Sigma,
UK) as a loading control. For the latter, the secondary
antibody was peroxidase-conjugated goat anti-mouse
immunoglobulin (DAKO, Glostrup, Denmark). The
amount of protein loaded has been specified in given fig-
ure legends. Optical density of the gels for all the treat-
ments was calculated using by Image-Pro Plus software
(Media Cybernetics).
Cell surface biotinylation
Following pharmacological treatment, cells were washed
three times with cold PBS. Live cells were incubated for 2
h with 1 mg/ml EZ-Link Sulfo-NHS-Biotin (Pierce, IL,
USA) at 4°C. After washing with PBS containing 10 mM
glycine, total cell protein was extracted, as before. One-
half of the extracted protein was kept at -20°C for Western
blots. The other half was labelled with streptavidin beads
for 1 h. Beads were washed extensively and re-suspended
in SDS sample buffer. Total and streptavin-labelled pro-
teins were subject to Western blots, as described above.
Immunocytochemistry and digital image analysis
Control or treated cells (2 × 104) were seeded onto13 mm
sterile coverslips (BHD, Poole, UK) pre-coated with poly-
L-lysine in 24 well plates and fixed in 4 % PFA for 15 min.
After washing (3 × 5 min with 0.1 % BSA in PBS; pH 7.4),
plasma membranes were stained with concanavalin A for
45 min [10]. After further washing (×3), cells were perme-
abilised with 0.1 % saponin for 3 min, washed and
blocked with 5 % BSA in PBS for 1 h at room temperature.
The primary antibody, pan-VGSCα (Upstate Biotechnol-
ogy, Buckingham, UK), diluted in 5 % BSA in PBS to the
working concentration (1 µg/100 µl), was applied for 1 h
at room temperature in a moist chamber and then washed
off. The secondary antibody (a peroxidase-conjugated
swine anti-rabbit immunoglobulin; DAKO, Glostrup,
Denmark) and Alexaflour 568 were applied for 1 h at
room temperature and then washed off. Finally, cells were
washed in distilled H2O and mounted with anti-fading
medium, Vectashield (Vector, Burlingame, USA). Cells
were examined by confocal microscopy (Leica DM IRBE).
Exposures and optical sectioning were identical for all the
treatments.
VGSC protein expression in plasma membrane was quan-
tified as the mean optical intensity of immunoreactivity of
permeabilized cell outlines, calculated using the "free-
form line profile" function (Lecia confocal software LCS
Lite; version 2.00) drawn around the cell surface, deter-
mined by concanavalin A staining. Randomly chosen 50
cells (from 3 repeats in each experiment) were analysed.
The subcellular distribution of VGSC protein was deter-
mined using the "straight line profile" function drawn
across the cytoplasm avoiding the nucleus, as described
previously [10]. Digitised optical density in plasma mem-
brane region, set to cover 1.5 µm inward from the edge of
concanavalin A staining, was compared with cytoplasmic
signal density within the central 30 % of the line profile.
Measurements were taken from randomly chosen 6 cells
per condition for three repeat experiments.
Data analysis
All data were analysed as means ± standard errors. Statis-
tical significance was determined using Student's t-test or
ANOVA with Newman-Keuls post-hoc analysis were used,
as appropriate. Results were considered significant for p <
0.05.
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